Back

Zealand Pharma reports up to 10.7% weight loss for petrelintide in Phase 2 trial

Verifying
  • Zealand Pharma published ZUPREME-1 petrelintide results and presented additional data at EASD 2026.
  • Petrelintide reduced mean body weight by up to 10.7% versus 1.7% for placebo at week 42.
  • Zealand Pharma initiated a global Phase 3 ZUPREME program for petrelintide monotherapy.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.